Poxel Appoints Jonae R. Barnes as Senior Vice President Investor Relations and Public Relations, Based in Boston

Download as PDF

LYON, France--(BUSINESS WIRE)-- Poxel SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that Jonae R. Barnes has joined the Company as Senior Vice President, Investor Relations and Public Relations. Ms. Barnes will be based in the Boston area, a leading area in drug development and innovation.

“We are delighted to welcome Jonae to Poxel in a senior leadership role as we continue to advance the Company and build our US presence,” said Thomas Kuhn, CEO of Poxel. “Jonae has a strong track record of raising the visibility and helping to build successful pharmaceutical and biotechnology companies in the US, and has a long history of working with the financial community. Jonae will be teaming up with Noah Beerman to help build our footprint in the US and will work closely with the leadership team headquartered in France.”

“Poxel is at an inflection point as the Company continues to advance its lead drug candidate Imeglimin, for the treatment of type 2 diabetes, into late-stage trials and move forward with its Phase 1 program for PXL770, another first-in-class drug candidate,” commented Ms. Barnes. “I am excited to work with the experienced team at Poxel as the Company approaches multiple key data readouts anticipated over the next 12 to 18 months.”

Ms. Barnes has 20 years of experience in the pharmaceutical and biotechnology industry. Her experience in strategic investor and corporate communications spans the full life cycle of drug development and commercialization. She began her career at Sepracor (now Sunovion Pharmaceuticals; acquired by Dainippon Sumitomo Pharma Co. for approximately $3 billion in 2009), a specialty pharmaceutical company, where she held a series of progressively responsible management and executive roles over a 14-year period and most recently served as Senior Vice President, Investor Relations, Corporate Communications and Internal Communications. Ms. Barnes has also served in senior leadership roles at Agenus, an immuno-oncology company and Vision Medicines, an ophthalmology-focused company. In addition to her corporate appointments, Jonae has advised privately held and publicly traded biotech companies through her investor relations consulting practice in the therapeutic areas of respiratory disorders, infectious diseases, IBS, diabetes and oncology. Jonae holds a bachelor’s degree in political science from Suffolk University and master’s degrees in financial economics and multinational commerce from Boston University.

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has initiated Phase 2b development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext:POXEL, www.poxel.com)

Poxel SA
Jonae Barnes, + 1 617 818 2985
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
+ 49 89 2424 3494 or + 49 175 571 1562
smay@macbiocom.com
or
Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr

Source: Poxel

Released March 14, 2016